Emyria Ltd (EMD)

Snapshot

EMD's Principal Activity is the provide care for its patients through Emeralds specialist clinics whilst gathering Real-World-Evidence (RWE) insights in relation to novel therapies such as medicinal cannabinoids and drug development.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Dr Karen Smith	Non-Executive Director	Nov 2021	Dr Karen Smith Non-Executive Director Dr Smith has overseen more than 100 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including neuroscience, rare disease, oncology, cardiology, dermatology, oncology and anti-infectives. In addition to R&D and pipeline development, her experience includes the acquisition of U.S. and international companies, divestitures and negotiating partnership deals between biotech and pharma. Dr Smith was recently Chief Medical Officer of Emergent BioSolutions. Dr Smith is also a Director at Antares Pharmaceuticals - developing novel drug delivery technologies and Sangamo Therapeutics and Acceleron Pharmaceuticals - both developing novel treatments for rare diseases, and TeeFib - developing novel treatments for Fibrosis. Previously, Dr Smith served as Executive Vice President, Global Head R&D and Chief Medical Officer of Jazz Pharmaceuticals, Inc. She was also the founding CEO of the Minderoo Foundation's Eliminate Cancer Initiative supported by Andrew Forrest and remains an advisor to that program. She has also held senior leadership positions at Allergan plc, AstraZeneca and Bristol-Myers Squibb.
Sir John Tooke	Non-Executive Director	Feb 2020	Sir John Tooke Non-Executive Director Sir Tooke is Executive Chairman of Academic Health Solutions, a start-up Group offering advice to clients internationally on medical research and health service transformation. He is Senior Independent Director at BUPA Chile and was until 2019 non-executive director of the BUPA main Board and the Chair of the Medical Advisory Council. He is the Chair of Collaboration for the Advancement of Medical Innovation (CASMI) UCL and Chaired the Oversight Group for the Academy of Medical Sciences project. He also served as an Review Board Member for Google Health (UK). Sir Tooke was Head of the School of Life and Medical Sciences at University College London (UCL) as Vice Provost (Health) and Academic Director of UCL Partners from 2010 - 2015. He is the Past President of the Academy of Medical Sciences in the UK. Sir Tooke has 30 years experience as a consultant physician specialising in diabetes, endocrinology, vascular medicine and internal medicine with research experience (basic biomedical, medicine, and health research and also includes improvement science) recognised through Fellowship of the Academy of Medical Sciences. He held a Board position at the Francis Crick Institute (2011 - 2015) and was a Member of the Council for Science & Technology (2011-2015) reporting to the Prime Minister (UK).
Dr Michael Winlo	Managing Director	Nov 2019	Dr Michael Winlo Managing Director Dr Winlo was CEO at Linear Clinical Research Ltd (Linear) until October 2019, a company that provides clinical trial services for US and Asia-based biotech companies. Linear adopt electronic data capture technology. Dr Winlo retains a Directorship at Linear. Prior to Linear, He was Health Lead at Palantir Technologies, a Big Data company based in Silicon Valley California.
Dr Alistair Vickery	Executive Director	Nov 2018	Dr Alistair Vickery Executive Director Dr Vickery has expertise in clinical practice, health service management, clinical and educational research and board director skills. He is adjunct Clinical Professor of Primary Health Care at the University of Western Australia and Notre Dame University. He is the clinical lead of the research group CHASM (The Collaborative for Health Care Analysis and Statistical Modelling) which provides analysis modelling to inform clinical service planning and service evaluation. He is Board Chair of Black Swan Health, one of NFP health care service providers in Western Australia.
Mr Matthew (Matt) Callahan	Non-Executive Director	Mar 2018	Mr Matthew (Matt) Callahan Non-Executive Director Mr Callahan is a life sciences executive with experience. He has been the founder, CEO or Executive Director of a number of pharmaceutical and health tech companies which includes Churchill Pharma Inc. He has led the development of four pharmaceutical products that have received FDA approval and he has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in lifesciences, technology and other sectors.
Dr Stewart James Washer	Executive Chairman,Executive Director	Mar 2018	Dr Stewart James Washer Executive Chairman,Executive Director Dr Washer has 25 years of CEO and Board experience in medical and agrifood biotech companies. Stewart has held a number of Board positions in the past, including Chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to a US Pharma. He was also a Senator with Murdoch University and was a Director of AusBiotech Ltd.
Mr Simon Lee Robertson	Company Secretary	N/A
Su-Mei Sain	Chief Financial Officer	N/A
Patrizia Washer	Research Manager	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
13/11/20	John Tooke	Issued	1,000,000	$0.076	$76,000	Issue of options
13/11/20	Matthew (Matt) Callahan	Issued	1,500,000	$0.076	$114,000	Issue of options
13/11/20	Alistair Vickery	Issued	2,000,000	$0.076	$152,000	Issue of options
13/11/20	Michael Winlo	Issued	4,000,000	$0.076	$304,000	Issue of options
12/11/20	Stewart Washer	Buy	+255,000	$0.08	$20,321	On-market trade
11/11/20	Stewart Washer	Buy	+150,000	$0.082	$12,283	On-market trade
10/11/20	Stewart Washer	Buy	+100,000	$0.08	$7,986	On-market trade
09/11/20	Stewart Washer	Buy	+270,000	$0.077	$20,765	On-market trade
19/10/20	Alistair Vickery	Buy	+128,000	$0.078	$10,002	On-market trade
16/03/20	Stewart Washer	Buy	+100,000	$0.061	$6,110	On-market trade
16/03/20	Stewart Washer	Buy	+100,000	$0.061	$6,110	On-market trade
10/03/20	Stewart Washer	Buy	+58,500	$0.09	$5,290	On-market trade
09/03/20	Stewart Washer	Buy	+120,500	$0.089	$10,668	On-market trade
06/03/20	Stewart Washer	Buy	+271,499	$0.089	$24,182	On-market trade
06/03/20	Stewart Washer	Buy	+271,499	$0.089	$24,182	On-market trade

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Karen Smith	29/11/2021	N/A	N/A	1,500,000	N/A
Alistair Vickery	30/06/2021	N/A	128,000	4,000,000	N/A
Michael Winlo	30/06/2021	N/A	N/A	7,500,000	N/A
John Tooke	30/06/2021	N/A	N/A	1,500,000	N/A
Stewart Washer	30/06/2021	N/A	49,325,589	N/A	N/A
Matthew (Matt) Callahan	30/06/2021	N/A	19,600,000	1,500,000	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Dr Stewart James Washer & Dr Patrizia Derna Washer	28,400,000	11.18%
Mal Washer Nominees Pty Ltd	19,600,000	7.71%
Mercator Shipwrights Pty Ltd	19,600,000	7.71%
Mr Craig Lawrence Darby	19,600,000	7.71%
Mr Sufian Ahmad	10,276,210	4.04%
Miss Sihong Zeng	6,523,385	2.57%
Ms Chunyan Niu	5,882,546	2.32%
Lakewest Pty Ltd	5,731,960	2.26%
Mr Stephen Peter Somerville	4,900,000	1.93%
Rimoyne Pty Ltd	3,831,244	1.51%
Woodlands Opportunity Fund Pty Ltd	3,551,757	1.40%
Mr Bilal Ahmad	3,450,000	1.36%
Mr Pak Lim Kong	3,416,667	1.34%
Kobala Investments Pty Ltd	2,600,000	1.02%
Mr Lim Pak Kong	2,370,930	0.93%
Mr Craig Lawrence Darby i	2,000,000	0.79%
Adam James(Araucaria A/C)	1,960,000	0.77%
D Schecter Medicine Professional Corporation	1,960,000	0.77%
Cs Fourth Nominees Pty Limited	1,683,576	0.66%
Canopy Growth Corporation	1,562,500	0.61%
Diab Investments Pty Ltd	1,554,622	0.61%
Mr Boyun Liu	1,549,962	0.61%
Dr Stewart James Washer & Dr Patrizia Derna Washer i	1,325,599	0.52%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.048	30 June

EMD Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.